Drug Repurposing for the Prevention of Chemotherapy-induced Peripheral Neuropathy (CIPN)
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
Chemotherapy cause many adverse events including induction of peripheral neuropathy.
Metformin, the AMPK activator, was found to have protective effect against chemotherapy
induced peripheral neuropathy in mouse model and in clinical trials as well. There are
different hypothesized mechanisms through which metformin does the protective effect. Such as
enhancing mitochondrial activity, reduction of ROS and nitric oxide and activation of AMPK.